Masha Maharaj

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P. Baum et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 124 citations · Full text

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

Hojjat Ahmadzadehfar, Ralf Matern, Richard P. Baum et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 36 citations

Bone Disease, Oncology, Bone Health +11

Primary Osteogenic Sarcoma of the Breast Detected on Skeletal Scintigraphy

A Ellmann, Zabah Jawa, Masha Maharaj · Clinical Nuclear Medicine · 2006 · 18 citations

74-Year-old Woman, Surgical Oncology, Breast Oncology +12

The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report

Masha Maharaj, Lucille Heslop, Trisha Govender et al. · Nuclear Medicine and Molecular Imaging · 2021 · 17 citations · Full text

Urology, Radiation Medicine, Low-dose Docetaxel +11